Activating RAS mutations drive a substantial proportion of human cancers, yet for decades RAS was considered undruggable. The recent development of tri-complex inhibitors (TCIs) such as daraxonrasib (RMC-6236) has transformed the therapeutic landscape by enabling potent, multi-selective targeting of the active, GTP-bou...
Jiacheng Lou, Dan Zhang· Experimental Hematology & On...· 0 citations
Protein farnesylation, catalyzed by farnesyltransferase (FTase), covalently attaches a 15-carbon farnesyl lipid to cysteine residues within C-terminal CaaX motifs. This modification governs the subcellular localization, protein–protein interactions, and activity of diverse eukaryotic proteins, including Ras GTPases, nu...
Jiacheng Lou, Dan Zhang, Ying-Jie Wang· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.